Immunic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Immunic şirketinin toplam hissedar öz sermayesi $151.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $189.7M ve $38.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$186.63m
Eşitlik	US$151.23m
Toplam yükümlülükler	US$38.51m
Toplam varlıklar	US$189.74m

Son finansal sağlık güncellemeleri

Analiz Makalesi • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Recent updates

Analiz Makalesi • Oct 17

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.

Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.

Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2 $88.1 million.

Analiz Makalesi • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IMUX 'nin kısa vadeli varlıkları ( $188.8M ) kısa vadeli yükümlülüklerini ( $38.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: IMUX şirketinin kısa vadeli varlıkları ( $188.8M ) uzun vadeli yükümlülüklerini ( $146.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IMUX borçsuzdur.

Borcun Azaltılması: IMUX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IMUX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: IMUX serbest nakit akışı her yıl % 10.3 1.5 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/22 11:37
Gün Sonu Hisse Fiyatı	2026/06/22 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Immunic, Inc. 18 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
George Farmer	BMO Capital Markets Equity Research
William Wood	B. Riley Securities, Inc.
Tyler Bussian	Brookline Capital Markets

Immunic Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price Rule

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Receives Notice of Nasdaq Non-Compliance with Minimum Bid Price Requirement

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Recent updates

Immunic, Inc., Annual General Meeting, Jun 29, 2026

Immunic, Inc. Announces Chief Executive Officer Changes

Price target decreased by 10% to US$44.67

Immunic, Inc. Appoints Michael W. Bonney as Chair of the Board of Directors, Effective May 16, 2026

Immunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026

Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026

Price target increased by 11% to US$5.00

No longer forecast to breakeven

New major risk - Negative shareholders equity

Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investors

Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple Sclerosis

Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investors

Immunic, Inc. Plans Transition of Daniel Vitt from CEO

New minor risk - Share price stability

Immunic to Present Additional Phase 2 Calliper Trial Data Foridofludimus Calcium At the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price Rule

Immunic, Inc.'s Subsidiary Gliomic Therapeutics Inc. Announces Executive Appointments, Effective January 1, 2026

Forecast to breakeven in 2028

New major risk - Shareholder dilution

New minor risk - Profitability

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Price target decreased by 11% to US$6.83

Immunic, Inc. Presents Key Vidofludimus Calcium Data At the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

New major risk - Financial position

No longer forecast to breakeven

Immunic, Inc. Receives Notice of Nasdaq Non-Compliance with Minimum Bid Price Requirement

Immunic, Inc. Reports New, Positive Long-Term Open-Label Extension Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Independent Director recently bought US$100k worth of stock

Immunic, Inc. Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 Calliper Trial in Progressive MS

Price target decreased by 8.3% to US$12.55

Immunic, Inc. has announced a Derivatives Offering.

New major risk - Negative shareholders equity

New minor risk - Share price stability

Immunic, Inc. Announces Positive Data from Phase 2 Calliper Trial of Nurr1 (Nurr1) Activator,Idofludimus Calcium (Imu-838) in Patients with Progressive Multiple Sclerosis

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc., Annual General Meeting, Jun 04, 2025

Immunic, Inc. has completed a Follow-on Equity Offering in the amount of $5.1 million.

Immunic, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Price target increased by 7.0% to US$13.12

Immunic, Inc.'s Oral IMU-856 Demonstrates Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

New minor risk - Market cap size

Independent Director recently bought US$100k worth of stock

No longer forecast to breakeven

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026